Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04925713 · ClinicalTrials.gov registry record · Phase 1
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
A Phase 1 study, sponsored by TuHURA Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04925713: Completed Phase 1 study, sponsored by TuHURA Biosciences.
NCT04925713 is a Phase 1 study that has completed, run by TuHURA Biosciences. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04925713, a Phase 1 study, has completed, sponsored by TuHURA Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
One hundred patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion. These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-5 days) for any delayed adverse events..
Primary Outcome
Rate of Adverse Events reported per Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Interventions
- BIOLOGICAL IFx-Hu2.0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-06-10 |
| Est. Completion | 2022-03-10 |
| Phase | Phase 1 |
What the finished NCT04925713 record still lists
NCT04925713 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which IFx-Hu2.0 is the first listed.
NCT04925713 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04925713 about?
NCT04925713 is a clinical study titled "IFx-Hu2.0 for the Treatment of Patients With Skin Cancer". One hundred patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion. These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-5 days) for any delayed adverse events..
What is the current status of trial NCT04925713?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2021-06-10. Estimated completion is 2022-03-10.
What interventions are being tested in trial NCT04925713?
The interventions under investigation include: IFx-Hu2.0 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04925713?
This trial is sponsored by TuHURA Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04925713's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI